Financings in Brief: Metra Biosystems
This article was originally published in The Gray Sheet
Executive Summary
Metra Biosystems: Completes a secondary stock offering of 2 mil. shares for $13.50 each. Metra, which filed a registration statement for the offering in March, plans to use proceeds for "working capital and general corporate purposes, including expanding sales and marketing efforts," and funding of product launches, clinical studies, research and development and complementary technology or business acquisitions, the firm says. In addition to marketing its current products for detection and management of metabolic bone diseases and disorders, Metra is actively pursuing the development of a range of new products including cartilage, bone and connective tissue disorder tests. The offering was underwritten by Cowen & Co., Robertson, Stephens & Co. and Hambrecht & Quist...
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.